A Phase II Study of Pazopanib and Oral Topotecan in Women With Recurrent Cervical Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Pazopanib (Primary) ; Topotecan
- Indications Cervical cancer
- Focus Therapeutic Use
- 15 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Apr 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Aug 2019.
- 19 Apr 2016 Planned initiation date changed from 1 Feb 2016 to 1 Aug 2016.